Tiziana Life Sciences PLC Sponsored ADR (TLSA)

Last Price: 3.93 (2020-09-18)

Company Description

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-9.32M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) --
Current Ratio (Most Recent Fiscal Quarter) 0.20
Quick Ratio (Most Recent Fiscal Quarter) 0.20
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $-0.09
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) $-0.03
Diluted Earnings per Share (Trailing 12 Months) --
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 64.22M
Free Float --
Market Capitalization $238.26M
Average Volume (Last 20 Days) 0.32M
Beta (Past 60 Months) 2.23
Percentage Held By Insiders (Latest Annual Proxy Report) --
Percentage Held By Institutions (Latest 13F Reports) 2.21%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%